APO Research
Talk to an analyst

APO RESEARCH · REPORT

Infectious Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Infectious Vaccines Market Analysis and Forecast 2026-2032

22 December 2025194 pages

Choose your research edition.

Industry ResearchInfectious Vaccines Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Infectious Vaccines Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Infectious Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Infectious Vaccines Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Infectious Vaccines Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Infectious Vaccines market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Infectious Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Infectious Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Infectious Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Infectious Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Infectious Vaccines include Sanofi Pasteur (France), Johnson and Johnson (U.S.), Novartis AG (Switzerland), Merck and Company (U.S.), Pfizer Inc. (U.S.), GlaxoSmithKline plc. (U.K.), MedImmune LLC (U.S.), Emergent Bio Solutions Inc. (U.S.) and CSL Limited (Australia), etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Infectious Vaccines, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Infectious Vaccines, also provides the sales of main regions and countries. Of the upcoming market potential for Infectious Vaccines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Infectious Vaccines sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Infectious Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Infectious Vaccines sales, projected growth trends, production technology, application and end-user industry.

Infectious Vaccines Segment by Company

Sanofi Pasteur (France)

Johnson and Johnson (U.S.)

Novartis AG (Switzerland)

Merck and Company (U.S.)

Pfizer Inc. (U.S.)

GlaxoSmithKline plc. (U.K.)

MedImmune LLC (U.S.)

Emergent Bio Solutions Inc. (U.S.)

CSL Limited (Australia)

Bavarian Nordic (Denmark)

Infectious Vaccines Segment by Type

Preventive Vaccine

Therapeutic Vaccine

Infectious Vaccines Segment by Application

Adults

Pediatrics

Infectious Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Infectious Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Infectious Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Infectious Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Infectious Vaccines in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Infectious Vaccines manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Infectious Vaccines sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Infectious Vaccines Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Preventive Vaccine Major Manufacturers Table 3. Therapeutic Vaccine Major Manufacturers Table 4. Global Infectious Vaccines Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Adults Major Manufacturers Table 6. Pediatrics Major Manufacturers Table 7. Infectious Vaccines Industry Trends Table 8. Infectious Vaccines Industry Drivers Table 9. Infectious Vaccines Industry Opportunities and Challenges Table 10. Infectious Vaccines Industry Restraints Table 11. Global Infectious Vaccines Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 12. Global Infectious Vaccines Revenue by Region (2021-2026) & (US$ Million) Table 13. Global Infectious Vaccines Revenue by Region (2027-2032) & (US$ Million) Table 14. Global Infectious Vaccines Revenue Market Share by Region (2021-2026) Table 15. Global Infectious Vaccines Revenue Market Share by Region (2027-2032) Table 16. Global Infectious Vaccines Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 17. Global Infectious Vaccines Sales by Region (2021-2026) & (k units) Table 18. Global Infectious Vaccines Sales by Region (2027-2032) & (k units) Table 19. Global Infectious Vaccines Sales Market Share by Region (2021-2026) Table 20. Global Infectious Vaccines Sales Market Share by Region (2027-2032) Table 21. Global Infectious Vaccines Revenue by Manufacturers (US$ Million) & (2021-2026) Table 22. Global Infectious Vaccines Revenue Market Share by Manufacturers (2021-2026) Table 23. Global Infectious Vaccines Sales by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Infectious Vaccines Sales Market Share by Manufacturers (2021-2026) Table 25. Global Infectious Vaccines Sales Price (US$/unit) of Manufacturers (2021-2026) Table 26. Global Infectious Vaccines Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 27. Global Infectious Vaccines Key Manufacturers Manufacturing Sites & Headquarters Table 28. Global Infectious Vaccines Manufacturers, Product Type & Application Table 29. Global Infectious Vaccines Manufacturers' Establishment Date Table 30. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 31. Global Infectious Vaccines by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 32. Global Infectious Vaccines Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Infectious Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 34. Global Infectious Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 35. Global Infectious Vaccines Revenue Market Share by Type (2021-2026) Table 36. Global Infectious Vaccines Revenue Market Share by Type (2027-2032) Table 37. Global Infectious Vaccines Sales by Type 2021 VS 2025 VS 2032 (k units) Table 38. Global Infectious Vaccines Sales by Type (2021-2026) & (k units) Table 39. Global Infectious Vaccines Sales by Type (2027-2032) & (k units) Table 40. Global Infectious Vaccines Sales Market Share by Type (2021-2026) Table 41. Global Infectious Vaccines Sales Market Share by Type (2027-2032) Table 42. Global Infectious Vaccines Price by Type (2021-2026) & (US$/unit) Table 43. Global Infectious Vaccines Price by Type (2027-2032) & (US$/unit) Table 44. Global Infectious Vaccines Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 45. Global Infectious Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 46. Global Infectious Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 47. Global Infectious Vaccines Revenue Market Share by Application (2021-2026) Table 48. Global Infectious Vaccines Revenue Market Share by Application (2027-2032) Table 49. Global Infectious Vaccines Sales by Application 2021 VS 2025 VS 2032 (k units) Table 50. Global Infectious Vaccines Sales by Application (2021-2026) & (k units) Table 51. Global Infectious Vaccines Sales by Application (2027-2032) & (k units) Table 52. Global Infectious Vaccines Sales Market Share by Application (2021-2026) Table 53. Global Infectious Vaccines Sales Market Share by Application (2027-2032) Table 54. Global Infectious Vaccines Price by Application (2021-2026) & (US$/unit) Table 55. Global Infectious Vaccines Price by Application (2027-2032) & (US$/unit) Table 56. Sanofi Pasteur (France) Company Information Table 57. Sanofi Pasteur (France) Business Overview Table 58. Sanofi Pasteur (France) Infectious Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 59. Sanofi Pasteur (France) Infectious Vaccines Product Portfolio Table 60. Sanofi Pasteur (France) Recent Development Table 61. Johnson and Johnson (U.S.) Company Information Table 62. Johnson and Johnson (U.S.) Business Overview Table 63. Johnson and Johnson (U.S.) Infectious Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 64. Johnson and Johnson (U.S.) Infectious Vaccines Product Portfolio Table 65. Johnson and Johnson (U.S.) Recent Development Table 66. Novartis AG (Switzerland) Company Information Table 67. Novartis AG (Switzerland) Business Overview Table 68. Novartis AG (Switzerland) Infectious Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 69. Novartis AG (Switzerland) Infectious Vaccines Product Portfolio Table 70. Novartis AG (Switzerland) Recent Development Table 71. Merck and Company (U.S.) Company Information Table 72. Merck and Company (U.S.) Business Overview Table 73. Merck and Company (U.S.) Infectious Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 74. Merck and Company (U.S.) Infectious Vaccines Product Portfolio Table 75. Merck and Company (U.S.) Recent Development Table 76. Pfizer Inc. (U.S.) Company Information Table 77. Pfizer Inc. (U.S.) Business Overview Table 78. Pfizer Inc. (U.S.) Infectious Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 79. Pfizer Inc. (U.S.) Infectious Vaccines Product Portfolio Table 80. Pfizer Inc. (U.S.) Recent Development Table 81. GlaxoSmithKline plc. (U.K.) Company Information Table 82. GlaxoSmithKline plc. (U.K.) Business Overview Table 83. GlaxoSmithKline plc. (U.K.) Infectious Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 84. GlaxoSmithKline plc. (U.K.) Infectious Vaccines Product Portfolio Table 85. GlaxoSmithKline plc. (U.K.) Recent Development Table 86. MedImmune LLC (U.S.) Company Information Table 87. MedImmune LLC (U.S.) Business Overview Table 88. MedImmune LLC (U.S.) Infectious Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 89. MedImmune LLC (U.S.) Infectious Vaccines Product Portfolio Table 90. MedImmune LLC (U.S.) Recent Development Table 91. Emergent Bio Solutions Inc. (U.S.) Company Information Table 92. Emergent Bio Solutions Inc. (U.S.) Business Overview Table 93. Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Product Portfolio Table 95. Emergent Bio Solutions Inc. (U.S.) Recent Development Table 96. CSL Limited (Australia) Company Information Table 97. CSL Limited (Australia) Business Overview Table 98. CSL Limited (Australia) Infectious Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 99. CSL Limited (Australia) Infectious Vaccines Product Portfolio Table 100. CSL Limited (Australia) Recent Development Table 101. Bavarian Nordic (Denmark) Company Information Table 102. Bavarian Nordic (Denmark) Business Overview Table 103. Bavarian Nordic (Denmark) Infectious Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 104. Bavarian Nordic (Denmark) Infectious Vaccines Product Portfolio Table 105. Bavarian Nordic (Denmark) Recent Development Table 106. North America Infectious Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 107. North America Infectious Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 108. North America Infectious Vaccines Sales by Type (2021-2026) & (k units) Table 109. North America Infectious Vaccines Sales by Type (2027-2032) & (k units) Table 110. North America Infectious Vaccines Sales Price by Type (2021-2026) & (US$/unit) Table 111. North America Infectious Vaccines Sales Price by Type (2027-2032) & (US$/unit) Table 112. North America Infectious Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 113. North America Infectious Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 114. North America Infectious Vaccines Sales by Application (2021-2026) & (k units) Table 115. North America Infectious Vaccines Sales by Application (2027-2032) & (k units) Table 116. North America Infectious Vaccines Sales Price by Application (2021-2026) & (US$/unit) Table 117. North America Infectious Vaccines Sales Price by Application (2027-2032) & (US$/unit) Table 118. North America Infectious Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 119. North America Infectious Vaccines Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 120. North America Infectious Vaccines Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 121. North America Infectious Vaccines Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 122. North America Infectious Vaccines Sales by Country (2021-2026) & (k units) Table 123. North America Infectious Vaccines Sales by Country (2027-2032) & (k units) Table 124. North America Infectious Vaccines Sales Price by Country (2021-2026) & (US$/unit) Table 125. North America Infectious Vaccines Sales Price by Country (2027-2032) & (US$/unit) Table 126. United States Infectious Vaccines Revenue (2021-2032) & (US$ Million) Table 127. Canada Infectious Vaccines Revenue (2021-2032) & (US$ Million) Table 128. Mexico Infectious Vaccines Revenue (2021-2032) & (US$ Million) Table 129. Europe Infectious Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 130. Europe Infectious Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 131. Europe Infectious Vaccines Sales by Type (2021-2026) & (k units) Table 132. Europe Infectious Vaccines Sales by Type (2027-2032) & (k units) Table 133. Europe Infectious Vaccines Sales Price by Type (2021-2026) & (US$/unit) Table 134. Europe Infectious Vaccines Sales Price by Type (2027-2032) & (US$/unit) Table 135. Europe Infectious Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 136. Europe Infectious Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 137. Europe Infectious Vaccines Sales by Application (2021-2026) & (k units) Table 138. Europe Infectious Vaccines Sales by Application (2027-2032) & (k units) Table 139. Europe Infectious Vaccines Sales Price by Application (2021-2026) & (US$/unit) Table 140. Europe Infectious Vaccines Sales Price by Application (2027-2032) & (US$/unit) Table 141. Europe Infectious Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 142. Europe Infectious Vaccines Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 143. Europe Infectious Vaccines Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 144. Europe Infectious Vaccines Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 145. Europe Infectious Vaccines Sales by Country (2021-2026) & (k units) Table 146. Europe Infectious Vaccines Sales by Country (2027-2032) & (k units) Table 147. Europe Infectious Vaccines Sales Price by Country (2021-2026) & (US$/unit) Table 148. Europe Infectious Vaccines Sales Price by Country (2027-2032) & (US$/unit) Table 149. Germany Infectious Vaccines Revenue (2021-2032) & (US$ Million) Table 150. France Infectious Vaccines Revenue (2021-2032) & (US$ Million) Table 151. U.K. Infectious Vaccines Revenue (2021-2032) & (US$ Million) Table 152. Italy Infectious Vaccines Revenue (2021-2032) & (US$ Million) Table 153. Russia Infectious Vaccines Revenue (2021-2032) & (US$ Million) Table 154. Spain Infectious Vaccines Revenue (2021-2032) & (US$ Million) Table 155. Netherlands Infectious Vaccines Revenue (2021-2032) & (US$ Million) Table 156. Switzerland Infectious Vaccines Revenue (2021-2032) & (US$ Million) Table 157. Sweden Infectious Vaccines Revenue (2021-2032) & (US$ Million) Table 158. Poland Infectious Vaccines Revenue (2021-2032) & (US$ Million) Table 159. China Infectious Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 160. China Infectious Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 161. China Infectious Vaccines Sales by Type (2021-2026) & (k units) Table 162. China Infectious Vaccines Sales by Type (2027-2032) & (k units) Table 163. China Infectious Vaccines Sales Price by Type (2021-2026) & (US$/unit) Table 164. China Infectious Vaccines Sales Price by Type (2027-2032) & (US$/unit) Table 165. China Infectious Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 166. China Infectious Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 167. China Infectious Vaccines Sales by Application (2021-2026) & (k units) Table 168. China Infectious Vaccines Sales by Application (2027-2032) & (k units) Table 169. China Infectious Vaccines Sales Price by Application (2021-2026) & (US$/unit) Table 170. China Infectious Vaccines Sales Price by Application (2027-2032) & (US$/unit) Table 171. Asia Infectious Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 172. Asia Infectious Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 173. Asia Infectious Vaccines Sales by Type (2021-2026) & (k units) Table 174. Asia Infectious Vaccines Sales by Type (2027-2032) & (k units) Table 175. Asia Infectious Vaccines Sales Price by Type (2021-2026) & (US$/unit) Table 176. Asia Infectious Vaccines Sales Price by Type (2027-2032) & (US$/unit) Table 177. Asia Infectious Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 178. Asia Infectious Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 179. Asia Infectious Vaccines Sales by Application (2021-2026) & (k units) Table 180. Asia Infectious Vaccines Sales by Application (2027-2032) & (k units) Table 181. Asia Infectious Vaccines Sales Price by Application (2021-2026) & (US$/unit) Table 182. Asia Infectious Vaccines Sales Price by Application (2027-2032) & (US$/unit) Table 183. Asia Infectious Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 184. Asia Infectious Vaccines Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 185. Asia Infectious Vaccines Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 186. Asia Infectious Vaccines Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 187. Asia Infectious Vaccines Sales by Country (2021-2026) & (k units) Table 188. Asia Infectious Vaccines Sales by Country (2027-2032) & (k units) Table 189. Asia Infectious Vaccines Sales Price by Country (2021-2026) & (US$/unit) Table 190. Asia Infectious Vaccines Sales Price by Country (2027-2032) & (US$/unit) Table 191. Japan Infectious Vaccines Revenue (2021-2032) & (US$ Million) Table 192. South Korea Infectious Vaccines Revenue (2021-2032) & (US$ Million) Table 193. India Infectious Vaccines Revenue (2021-2032) & (US$ Million) Table 194. Australia Infectious Vaccines Revenue (2021-2032) & (US$ Million) Table 195. Taiwan Infectious Vaccines Revenue (2021-2032) & (US$ Million) Table 196. Southeast Asia Infectious Vaccines Revenue (2021-2032) & (US$ Million) Table 197. SAMEA Infectious Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 198. SAMEA Infectious Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 199. SAMEA Infectious Vaccines Sales by Type (2021-2026) & (k units) Table 200. SAMEA Infectious Vaccines Sales by Type (2027-2032) & (k units) Table 201. SAMEA Infectious Vaccines Sales Price by Type (2021-2026) & (US$/unit) Table 202. SAMEA Infectious Vaccines Sales Price by Type (2027-2032) & (US$/unit) Table 203. SAMEA Infectious Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 204. SAMEA Infectious Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 205. SAMEA Infectious Vaccines Sales by Application (2021-2026) & (k units) Table 206. SAMEA Infectious Vaccines Sales by Application (2027-2032) & (k units) Table 207. SAMEA Infectious Vaccines Sales Price by Application (2021-2026) & (US$/unit) Table 208. SAMEA Infectious Vaccines Sales Price by Application (2027-2032) & (US$/unit) Table 209. SAMEA Infectious Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 210. SAMEA Infectious Vaccines Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 211. SAMEA Infectious Vaccines Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 212. SAMEA Infectious Vaccines Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 213. SAMEA Infectious Vaccines Sales by Country (2021-2026) & (k units) Table 214. SAMEA Infectious Vaccines Sales by Country (2027-2032) & (k units) Table 215. SAMEA Infectious Vaccines Sales Price by Country (2021-2026) & (US$/unit) Table 216. SAMEA Infectious Vaccines Sales Price by Country (2027-2032) & (US$/unit) Table 217. Brazil Infectious Vaccines Revenue (2021-2032) & (US$ Million) Table 218. Argentina Infectious Vaccines Revenue (2021-2032) & (US$ Million) Table 219. Chile Infectious Vaccines Revenue (2021-2032) & (US$ Million) Table 220. Colombia Infectious Vaccines Revenue (2021-2032) & (US$ Million) Table 221. Peru Infectious Vaccines Revenue (2021-2032) & (US$ Million) Table 222. Saudi Arabia Infectious Vaccines Revenue (2021-2032) & (US$ Million) Table 223. Israel Infectious Vaccines Revenue (2021-2032) & (US$ Million) Table 224. UAE Infectious Vaccines Revenue (2021-2032) & (US$ Million) Table 225. Turkey Infectious Vaccines Revenue (2021-2032) & (US$ Million) Table 226. Iran Infectious Vaccines Revenue (2021-2032) & (US$ Million) Table 227. Egypt Infectious Vaccines Revenue (2021-2032) & (US$ Million) Table 228. Key Raw Materials Table 229. Raw Materials Key Suppliers Table 230. Infectious Vaccines Distributors List Table 231. Infectious Vaccines Customers List Table 232. Research Programs/Design for This Report Table 233. Authors List of This Report Table 234. Secondary Sources Table 235. Primary Sources List of Figures Figure 1. Infectious Vaccines Image Figure 2. Global Infectious Vaccines Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Infectious Vaccines Market Size Share 2021 VS 2025 VS 2032 Figure 4. Preventive Vaccine Image Figure 5. Therapeutic Vaccine Image Figure 6. Global Infectious Vaccines Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Infectious Vaccines Market Size Share 2021 VS 2025 VS 2032 Figure 8. Adults Image Figure 9. Pediatrics Image Figure 10. Global Infectious Vaccines Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Infectious Vaccines Revenue (2021-2032) & (US$ Million) Figure 12. Global Infectious Vaccines Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 13. Global Infectious Vaccines Revenue Market Share by Region: 2025 Versus 2032 Figure 14. Global Infectious Vaccines Revenue Market Share by Region (2021-2032) Figure 15. Global Infectious Vaccines Sales (2021-2032) & (k units) Figure 16. Global Infectious Vaccines Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 17. Global Infectious Vaccines Sales Market Share by Region (2021-2032) Figure 18. US & Canada & Mexico Infectious Vaccines Sales YoY (2021-2032) & (k units) Figure 19. Europe Infectious Vaccines Sales YoY (2021-2032) & (k units) Figure 20. China Infectious Vaccines Sales YoY (2021-2032) & (k units) Figure 21. Asia (Excluding China) Infectious Vaccines Sales YoY (2021-2032) & (k units) Figure 22. South America, Middle East and Africa Infectious Vaccines Sales YoY (2021-2032) & (k units) Figure 23. Global Infectious Vaccines Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 24. Global Infectious Vaccines Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 25. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 26. Global Infectious Vaccines Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Infectious Vaccines Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 28. Global Infectious Vaccines Revenue Market Share by Type (2021-2032) Figure 29. Global Infectious Vaccines Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 30. Global Infectious Vaccines Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Infectious Vaccines Sales Market Share by Type (2021-2032) Figure 32. Global Infectious Vaccines Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 33. Global Infectious Vaccines Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 34. Global Infectious Vaccines Revenue Market Share by Application (2021-2032) Figure 35. Global Infectious Vaccines Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 36. Global Infectious Vaccines Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Infectious Vaccines Sales Market Share by Application (2021-2032) Figure 38. North America Infectious Vaccines Revenue Share by Type (2021-2032) Figure 39. North America Infectious Vaccines Sales Share by Type (2021-2032) Figure 40. North America Infectious Vaccines Revenue Share by Application (2021-2032) Figure 41. North America Infectious Vaccines Sales Share by Application (2021-2032) Figure 42. North America Infectious Vaccines Revenue Share by Country (2021-2032) Figure 43. North America Infectious Vaccines Sales Share by Country (2021-2032) Figure 44. Europe Infectious Vaccines Revenue Share by Type (2021-2032) Figure 45. Europe Infectious Vaccines Sales Share by Type (2021-2032) Figure 46. Europe Infectious Vaccines Revenue Share by Application (2021-2032) Figure 47. Europe Infectious Vaccines Sales Share by Application (2021-2032) Figure 48. Europe Infectious Vaccines Revenue Share by Country (2021-2032) Figure 49. Europe Infectious Vaccines Sales Share by Country (2021-2032) Figure 50. China Infectious Vaccines Revenue Share by Type (2021-2032) Figure 51. China Infectious Vaccines Sales Share by Type (2021-2032) Figure 52. China Infectious Vaccines Revenue Share by Application (2021-2032) Figure 53. China Infectious Vaccines Sales Share by Application (2021-2032) Figure 54. Asia Infectious Vaccines Revenue Share by Type (2021-2032) Figure 55. Asia Infectious Vaccines Sales Share by Type (2021-2032) Figure 56. Asia Infectious Vaccines Revenue Share by Application (2021-2032) Figure 57. Asia Infectious Vaccines Sales Share by Application (2021-2032) Figure 58. Asia Infectious Vaccines Revenue Share by Country (2021-2032) Figure 59. Asia Infectious Vaccines Sales Share by Country (2021-2032) Figure 60. SAMEA Infectious Vaccines Revenue Share by Type (2021-2032) Figure 61. SAMEA Infectious Vaccines Sales Share by Type (2021-2032) Figure 62. SAMEA Infectious Vaccines Revenue Share by Application (2021-2032) Figure 63. SAMEA Infectious Vaccines Sales Share by Application (2021-2032) Figure 64. SAMEA Infectious Vaccines Revenue Share by Country (2021-2032) Figure 65. SAMEA Infectious Vaccines Sales Share by Country (2021-2032) Figure 66. Infectious Vaccines Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Infectious Vaccines Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Preventive Vaccine
  • Therapeutic Vaccine
Applications
  • Adults
  • Pediatrics
Companies covered
  • Sanofi Pasteur (France)
  • Johnson and Johnson (U.S.)
  • Novartis AG (Switzerland)
  • Merck and Company (U.S.)
  • Pfizer Inc. (U.S.)
  • GlaxoSmithKline plc. (U.K.)
  • MedImmune LLC (U.S.)
  • Emergent Bio Solutions Inc. (U.S.)
  • CSL Limited (Australia)
  • Bavarian Nordic (Denmark)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Infectious Vaccines Market by Type
  3. 1.2.1 Global Infectious Vaccines Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Preventive Vaccine
  5. 1.2.3 Therapeutic Vaccine
  6. 1.3 Infectious Vaccines Market by Application
  7. 1.3.1 Global Infectious Vaccines Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Adults
  9. 1.3.3 Pediatrics
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Infectious Vaccines Market Dynamics
  1. 2.1 Infectious Vaccines Industry Trends
  2. 2.2 Infectious Vaccines Industry Drivers
  3. 2.3 Infectious Vaccines Industry Opportunities and Challenges
  4. 2.4 Infectious Vaccines Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Infectious Vaccines Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Infectious Vaccines Revenue by Region
  3. 3.2.1 Global Infectious Vaccines Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Infectious Vaccines Revenue by Region (2021-2026)
  5. 3.2.3 Global Infectious Vaccines Revenue by Region (2027-2032)
  6. 3.2.4 Global Infectious Vaccines Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Infectious Vaccines Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Infectious Vaccines Sales by Region
  9. 3.4.1 Global Infectious Vaccines Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Infectious Vaccines Sales by Region (2021-2026)
  11. 3.4.3 Global Infectious Vaccines Sales by Region (2027-2032)
  12. 3.4.4 Global Infectious Vaccines Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Infectious Vaccines Revenue by Manufacturers
  2. 4.1.1 Global Infectious Vaccines Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Infectious Vaccines Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Infectious Vaccines Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Infectious Vaccines Sales by Manufacturers
  6. 4.2.1 Global Infectious Vaccines Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Infectious Vaccines Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Infectious Vaccines Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Infectious Vaccines Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Infectious Vaccines Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Infectious Vaccines Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Infectious Vaccines Manufacturers, Product Type & Application
  13. 4.7 Global Infectious Vaccines Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Infectious Vaccines Market CR5 and HHI
  16. 4.8.2 2025 Infectious Vaccines Tier 1, Tier 2, and Tier 3
5 Infectious Vaccines Market by Type
  1. 5.1 Global Infectious Vaccines Revenue by Type
  2. 5.1.1 Global Infectious Vaccines Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Infectious Vaccines Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Infectious Vaccines Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Infectious Vaccines Sales by Type
  6. 5.2.1 Global Infectious Vaccines Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Infectious Vaccines Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global Infectious Vaccines Sales Market Share by Type (2021-2032)
  9. 5.3 Global Infectious Vaccines Price by Type
6 Infectious Vaccines Market by Application
  1. 6.1 Global Infectious Vaccines Revenue by Application
  2. 6.1.1 Global Infectious Vaccines Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Infectious Vaccines Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Infectious Vaccines Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Infectious Vaccines Sales by Application
  6. 6.2.1 Global Infectious Vaccines Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Infectious Vaccines Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global Infectious Vaccines Sales Market Share by Application (2021-2032)
  9. 6.3 Global Infectious Vaccines Price by Application
7 Company Profiles
  1. 7.1 Sanofi Pasteur (France)
  2. 7.1.1 Sanofi Pasteur (France) Company Information
  3. 7.1.2 Sanofi Pasteur (France) Business Overview
  4. 7.1.3 Sanofi Pasteur (France) Infectious Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Sanofi Pasteur (France) Infectious Vaccines Product Portfolio
  6. 7.1.5 Sanofi Pasteur (France) Recent Developments
  7. 7.2 Johnson and Johnson (U.S.)
  8. 7.2.1 Johnson and Johnson (U.S.) Company Information
  9. 7.2.2 Johnson and Johnson (U.S.) Business Overview
  10. 7.2.3 Johnson and Johnson (U.S.) Infectious Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Johnson and Johnson (U.S.) Infectious Vaccines Product Portfolio
  12. 7.2.5 Johnson and Johnson (U.S.) Recent Developments
  13. 7.3 Novartis AG (Switzerland)
  14. 7.3.1 Novartis AG (Switzerland) Company Information
  15. 7.3.2 Novartis AG (Switzerland) Business Overview
  16. 7.3.3 Novartis AG (Switzerland) Infectious Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Novartis AG (Switzerland) Infectious Vaccines Product Portfolio
  18. 7.3.5 Novartis AG (Switzerland) Recent Developments
  19. 7.4 Merck and Company (U.S.)
  20. 7.4.1 Merck and Company (U.S.) Company Information
  21. 7.4.2 Merck and Company (U.S.) Business Overview
  22. 7.4.3 Merck and Company (U.S.) Infectious Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Merck and Company (U.S.) Infectious Vaccines Product Portfolio
  24. 7.4.5 Merck and Company (U.S.) Recent Developments
  25. 7.5 Pfizer Inc. (U.S.)
  26. 7.5.1 Pfizer Inc. (U.S.) Company Information
  27. 7.5.2 Pfizer Inc. (U.S.) Business Overview
  28. 7.5.3 Pfizer Inc. (U.S.) Infectious Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Pfizer Inc. (U.S.) Infectious Vaccines Product Portfolio
  30. 7.5.5 Pfizer Inc. (U.S.) Recent Developments
  31. 7.6 GlaxoSmithKline plc. (U.K.)
  32. 7.6.1 GlaxoSmithKline plc. (U.K.) Company Information
  33. 7.6.2 GlaxoSmithKline plc. (U.K.) Business Overview
  34. 7.6.3 GlaxoSmithKline plc. (U.K.) Infectious Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 GlaxoSmithKline plc. (U.K.) Infectious Vaccines Product Portfolio
  36. 7.6.5 GlaxoSmithKline plc. (U.K.) Recent Developments
  37. 7.7 MedImmune LLC (U.S.)
  38. 7.7.1 MedImmune LLC (U.S.) Company Information
  39. 7.7.2 MedImmune LLC (U.S.) Business Overview
  40. 7.7.3 MedImmune LLC (U.S.) Infectious Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 MedImmune LLC (U.S.) Infectious Vaccines Product Portfolio
  42. 7.7.5 MedImmune LLC (U.S.) Recent Developments
  43. 7.8 Emergent Bio Solutions Inc. (U.S.)
  44. 7.8.1 Emergent Bio Solutions Inc. (U.S.) Company Information
  45. 7.8.2 Emergent Bio Solutions Inc. (U.S.) Business Overview
  46. 7.8.3 Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Product Portfolio
  48. 7.8.5 Emergent Bio Solutions Inc. (U.S.) Recent Developments
  49. 7.9 CSL Limited (Australia)
  50. 7.9.1 CSL Limited (Australia) Company Information
  51. 7.9.2 CSL Limited (Australia) Business Overview
  52. 7.9.3 CSL Limited (Australia) Infectious Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 CSL Limited (Australia) Infectious Vaccines Product Portfolio
  54. 7.9.5 CSL Limited (Australia) Recent Developments
  55. 7.10 Bavarian Nordic (Denmark)
  56. 7.10.1 Bavarian Nordic (Denmark) Company Information
  57. 7.10.2 Bavarian Nordic (Denmark) Business Overview
  58. 7.10.3 Bavarian Nordic (Denmark) Infectious Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Bavarian Nordic (Denmark) Infectious Vaccines Product Portfolio
  60. 7.10.5 Bavarian Nordic (Denmark) Recent Developments
8 North America
  1. 8.1 North America Infectious Vaccines Market Size by Type
  2. 8.1.1 North America Infectious Vaccines Revenue by Type (2021-2032)
  3. 8.1.2 North America Infectious Vaccines Sales by Type (2021-2032)
  4. 8.1.3 North America Infectious Vaccines Price by Type (2021-2032)
  5. 8.2 North America Infectious Vaccines Market Size by Application
  6. 8.2.1 North America Infectious Vaccines Revenue by Application (2021-2032)
  7. 8.2.2 North America Infectious Vaccines Sales by Application (2021-2032)
  8. 8.2.3 North America Infectious Vaccines Price by Application (2021-2032)
  9. 8.3 North America Infectious Vaccines Market Size by Country
  10. 8.3.1 North America Infectious Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Infectious Vaccines Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Infectious Vaccines Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Infectious Vaccines Market Size by Type
  2. 9.1.1 Europe Infectious Vaccines Revenue by Type (2021-2032)
  3. 9.1.2 Europe Infectious Vaccines Sales by Type (2021-2032)
  4. 9.1.3 Europe Infectious Vaccines Price by Type (2021-2032)
  5. 9.2 Europe Infectious Vaccines Market Size by Application
  6. 9.2.1 Europe Infectious Vaccines Revenue by Application (2021-2032)
  7. 9.2.2 Europe Infectious Vaccines Sales by Application (2021-2032)
  8. 9.2.3 Europe Infectious Vaccines Price by Application (2021-2032)
  9. 9.3 Europe Infectious Vaccines Market Size by Country
  10. 9.3.1 Europe Infectious Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Infectious Vaccines Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Infectious Vaccines Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Infectious Vaccines Market Size by Type
  2. 10.1.1 China Infectious Vaccines Revenue by Type (2021-2032)
  3. 10.1.2 China Infectious Vaccines Sales by Type (2021-2032)
  4. 10.1.3 China Infectious Vaccines Price by Type (2021-2032)
  5. 10.2 China Infectious Vaccines Market Size by Application
  6. 10.2.1 China Infectious Vaccines Revenue by Application (2021-2032)
  7. 10.2.2 China Infectious Vaccines Sales by Application (2021-2032)
  8. 10.2.3 China Infectious Vaccines Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Infectious Vaccines Market Size by Type
  2. 11.1.1 Asia Infectious Vaccines Revenue by Type (2021-2032)
  3. 11.1.2 Asia Infectious Vaccines Sales by Type (2021-2032)
  4. 11.1.3 Asia Infectious Vaccines Price by Type (2021-2032)
  5. 11.2 Asia Infectious Vaccines Market Size by Application
  6. 11.2.1 Asia Infectious Vaccines Revenue by Application (2021-2032)
  7. 11.2.2 Asia Infectious Vaccines Sales by Application (2021-2032)
  8. 11.2.3 Asia Infectious Vaccines Price by Application (2021-2032)
  9. 11.3 Asia Infectious Vaccines Market Size by Country
  10. 11.3.1 Asia Infectious Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Infectious Vaccines Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Infectious Vaccines Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Infectious Vaccines Market Size by Type
  2. 12.1.1 SAMEA Infectious Vaccines Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Infectious Vaccines Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Infectious Vaccines Price by Type (2021-2032)
  5. 12.2 SAMEA Infectious Vaccines Market Size by Application
  6. 12.2.1 SAMEA Infectious Vaccines Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Infectious Vaccines Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Infectious Vaccines Price by Application (2021-2032)
  9. 12.3 SAMEA Infectious Vaccines Market Size by Country
  10. 12.3.1 SAMEA Infectious Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Infectious Vaccines Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Infectious Vaccines Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Infectious Vaccines Value Chain Analysis
  2. 13.1.1 Infectious Vaccines Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Infectious Vaccines Production Mode & Process
  6. 13.2 Infectious Vaccines Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Infectious Vaccines Distributors
  9. 13.2.3 Infectious Vaccines Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst